Biotechnology is a rapidly evolving field, touching almost all parts of the human experience. The field has become a stronghold in the United States due to increased investment and a new multi-disciplinary approach to the developing research. Though these innovations are important for the future of disease prevention and the eradication of hunger and petrochemical dependence, it also leaves the door open to potential bioterrorism if these technologies get into the hands of bad actors. Currently, oversight for biosecurity in the US government is spread among multiple agencies without clear and streamlined protections and processes.
On January 29th, 2026, senators Tom Cotton (R-Arkansas) and Amy Klobuchar (D-Minnesota) introduced the Biosecurity Modernization and Innovation Act, a bipartisan bill aimed at closing some of the gaps in current biosecurity procedures. The bill has three main elements: the biosecurity element, the sandbox element, and the streamlining element.
The biosecurity element creates screening protocols and reporting requirements. The screening protocols are twofold: there are protocols for both DNA sequences and for customers. The protocols for sequences include creating lists of sequences that have potential for security concern, and updating and monitoring those sequences often. The protocols also require that each customer purchasing a sequence is properly vetted and screened before the sequence is given. The bill also creates safeguards for innovation, including expedited processing for institutions and exceptions for non-concerning sequences. The bill requires yearly reports to Congress and biyearly updates to standards.
The sandbox element directly impacts efforts to create innovation. Sandboxes are “environment[s] featuring short-term trials of proposed tests so that [researchers] can evaluate new regulatory pathways and potential improvements to existing pathways.” They allow for safe and efficient environments for technologies to be tested. The goal of this element is to create secure testing for innovation, and to foster participation of nongovernmental experts in the research and regulation process.
Finally, the streamlining element gets to the core of what biosecurity advocates have requested from the government. Science organizations, including the Federation of American Scientists and the Nuclear Threat Initiative have requested streamlined processes from the government because of the disjointed processes to protect sequences from getting into the hands of bad actors. The bill gives the White House 90 days after the law is enacted to assess the needs of biosecurity and identify gaps that need to be filled, followed by a period of implementation that includes further legislation or executive action if necessary.
The bill in its current state is a good first step toward biosecurity regulation in the quickly changing market. The government is making an effort to create long-term fixes to a problem that has before only received short-term band-aids. Its goal is to shift the burden from the researchers to the government, as the burden on researchers has inhibited efficient developments. Proponents of the bill state that this legislation is a step in the right direction, but make it clear that it is only a step, and that there is a lot more change that needs to be made to meet the quickly changing biotechnology environment. There is some concern about the short time period that the White House and executive branch are provided to start making discoveries and changes, but stakeholders find that the timeline matches the urgency that the issue requires.
It is obvious that this bill is the culmination of the leading senators listening to the requests of important stakeholders. It remains to be seen how this bill will fare in committee, but with bipartisan and stakeholder support, there is a sense of hope that this can kickstart rapid change that is urgently needed.